Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02635360 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer
A Phase 2 study, sponsored by Linda R Duska.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
NCT02635360: Completed Phase 2 study, sponsored by Linda R Duska.
NCT02635360 is a Phase 2 study that has completed, run by Linda R Duska. The registered enrollment target is 94 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02635360, a Phase 2 study, has completed, sponsored by Linda R Duska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.
Primary Outcome
Expression of immune markers measured at pre and post administration of study drug with chemoradiation will be compared, analyzed and enumerated using QuPath software to provide a cell #/mm2 (not per high power field) and the ratio of CD8+ cells:FoxP3+ cells/mm2 was calculated.
Interventions
- DRUG Pembrolizumab
- DRUG Cisplatin
- RADIATION Brachytherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2017-02-09 |
| Est. Completion | 2022-12-14 |
| Phase | Phase 2 |
What the finished NCT02635360 record still lists
NCT02635360 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (29% lower).
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT02635360 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02635360 about?
NCT02635360 is a clinical study titled "Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer". The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or du...
What is the current status of trial NCT02635360?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2017-02-09. Estimated completion is 2022-12-14.
What interventions are being tested in trial NCT02635360?
The interventions under investigation include: Pembrolizumab (DRUG), Cisplatin (DRUG), Brachytherapy (RADIATION).
Who is sponsoring clinical trial NCT02635360?
This trial is sponsored by Linda R Duska, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02635360's enrollment target sits among peer trials
94 764th of 2000 higher than 1,235 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI